Cerchietti Research Lab

Publications

Found 33 results

Filters: First Letter Of Last Name is V [Clear All Filters]

2024

Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al.. 2024. Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.

Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al.. 2024. Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.

Cancila V, Morello G, Bertolazzi G, Chan ASi-Yu, Bastianello G, Paysan D, Jaynes PWilliam, Schiavoni G, Mattei F, Piconese S et al.. 2024. Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.. Res Sq.

Maity D, Sivakumar N, Kamat P, Zamponi N, Min C, Du W, Jayatilaka H, Johnston A, Starich B, Agrawal A et al.. 2024. Profiling Dynamic Patterns of Single-Cell Motility.. Adv Sci (Weinh). :e2400918.

Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J et al.. 2024. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. Cancer Res. 84(1):101-117.

2023

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al.. 2023. Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al.. 2023. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.

2020

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

2018

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. 2018. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^.. Leuk Lymphoma. 59(1):256-258.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al.. 2018. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al.. 2018. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

2017

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al.. 2017. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. 2017. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al.. 2017. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

2016

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al.. 2016. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al.. 2016. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al.. 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

2015

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al.. 2015. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

2014

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ. 2014. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

2013

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al.. 2013. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al.. 2013. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al.. 2013. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al.. 2013. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.